Resverlogix Corp

RFS

Company Profile

  • Business description

    Resverlogix Corp clinical-stage biotechnology company. The company is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with chronic disease including cardiovascular disease (CVD) and associated comorbidities, and COVID-19.

  • Contact

    4820 Richard Road South West
    Suite 300
    CalgaryABT3E 6L1
    CAN

    T: +1 403 254-9252

    E: sarah@resverlogix.com

    https://www.resverlogix.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2024

    Employees

    18

Stocks News & Analysis

stocks

Microsoft earnings: Strength in cloud, guidance mixed

We think investors should be on board when Azure accelerates in the third quarter.
stocks

Chart of the week: Small caps lagging

This week's chart of the week comes from Morningstar's Market Strategist's take on small caps
stocks

An impending merger just raised our fair value for this ASX retail giant

The deal is set to deliver enhanced scale, cost savings and new synergies.  

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,379.7042.40-0.50%
CAC 407,409.1158.740.80%
DAX 4019,254.97177.430.93%
Dow JONES (US)42,052.19288.730.69%
FTSE 1008,177.1567.050.83%
HKSE20,506.43189.100.93%
NASDAQ18,239.92144.770.80%
Nikkei 22538,053.671,027.58-2.63%
NZX 50 Index12,559.2879.62-0.63%
S&P 5005,728.8023.350.41%
S&P/ASX 2008,118.8041.20-0.50%
SSE Composite Index3,272.017.81-0.24%

Market Movers